Robert Widrow, MD
Internal Medicine · Olympia, WANPI 1942341417
Payments from drug & device makers
Across 69 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$223
- GSK$192
- Johnson & Johnson$147
- AstraZeneca$138
- Amgen$127
- Pfizer$76
- plus $436 from 16 others
What the payments were for
- Food & beverage$1,333100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 8 | $223 |
| GSK | 6 | $192 |
| Johnson & Johnson | 5 | $147 |
| AstraZeneca | 11 | $138 |
| Amgen | 9 | $127 |
| Pfizer | 4 | $76 |
| Sanofi-aventis U.S. LLC | 4 | $62 |
| Astellas Pharma US Inc | 2 | $44 |
| Lilly USA, LLC | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $37 |
| AbbVie(2 entities) | 3 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Novartis | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Novo Nordisk | 1 | $23 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Merck | 1 | $17 |
| Eisai Inc. | 1 | $14 |
| Philips North America LLC | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,339 in reported general payments places this provider in the 90th percentile of 2,038 internal medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 103 | $79,891 |
| XareltoRivaroxaban | 43 | $55,690 |
| JardianceEmpagliflozin | 42 | $49,312 |
| MounjaroTirzepatide | 18 | $19,903 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,919 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $6,588 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $5,836 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,258 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 14 | $3,434 |
| Gabapentin | 224 | $3,375 |
| Levothyroxine Sodium | 200 | $3,313 |
| Metoprolol Succinate | 124 | $2,449 |
| Pantoprazole Sodium | 136 | $2,438 |
| Metformin Hcl | 211 | $2,195 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 121 | $2,099 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $76 | $79,891103 claims |
| Johnson & JohnsonXarelto | $147 | $55,69043 claims |
| Boehringer IngelheimJardiance | $223 | $49,31242 claims |
| Lilly USA, LLCMounjaro | $37 | $19,90318 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $192 | $13,17723 claims |
| AbbVieSynthroid | $37 | $1,73526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,038 internal medicine providers in Washington.
Other internal medicine in Olympia
- Sabrina BenjaminOlympia$7.9M
- Eric KleinOlympia$2.4M
- Shawna PurcellOlympia$294K
- Curtis ReinkeOlympia$14K
- Ryan AhernSeattle$7.3M
- Scott RamseySeattle$2M
- Vidya MenonTacoma$1.8M
- Peter ShalitSeattle$1.8M
- Yuan Po TuEverett$1.6M
- Peiqing QianSeattle$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.